Marinus Pharmaceuticals Valuation
Is MRNS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MRNS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MRNS * (MX$124) is trading below our estimate of fair value (MX$10258.78)
Significantly Below Fair Value: MRNS * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MRNS *?
Other financial metrics that can be useful for relative valuation.
What is MRNS *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$75.81m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.7x |
Enterprise Value/EBITDA | -0.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MRNS *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 17.7x | ||
LAB B Genomma Lab Internacional. de | 1x | 8.2% | Mex$16.2b |
ALA Arovella Therapeutics | 64x | n/a | AU$126.0m |
A204840 GL Pharm Tech | 3.4x | n/a | ₩89.8b |
RICH Laboratorios RichmondC.I.F | 2.3x | n/a | AR$80.3b |
MRNS * Marinus Pharmaceuticals | 2.7x | 42.9% | Mex$75.8m |
Price-To-Sales vs Peers: MRNS * is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (17.7x).
Price to Earnings Ratio vs Industry
How does MRNS *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Sales vs Industry: MRNS * is expensive based on its Price-To-Sales Ratio (2.7x) compared to the Global Pharmaceuticals industry average (2.5x).
Price to Sales Ratio vs Fair Ratio
What is MRNS *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2.7x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate MRNS *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.